T. Meyer
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
- Hepatology 76
- Hepatocellular Carcinoma Treatment and Prognosis 74
- Oncology 65
- Lung Cancer Research Studies 22
- Cancer Immunotherapy and Biomarkers 11
- Pancreatic and Hepatic Oncology Research 9
- Co-authors
- A. Vogel (12 shared papers)Andrew Kenneth Burroughs (16 shared papers)Anna Lena Saborowski (3 shared papers)Gonzalo Sapisochín (2 shared papers)Riad Salem (1 shared paper)Josep Maria Llovet (10 shared papers)Gordon J.S. Rustin (3 shared papers)Martyn Evan Caplin (32 shared papers)
- Journals
- Annals of Oncology (27 papers)Journal of Hepatology (18 papers)British Journal of Cancer (14 papers)European Journal of Cancer (8 papers)Endocrine Related Cancer (6 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
T. Meyer
191 papers receiving 14.0k citations
T. Meyer's Hit Papers
Peers
Comparison fields: 5 of 131
- Hepatology 6.0k
- Oncology 3.4k
- Cancer Research 1.5k
- Epidemiology 3.0k
- Pathology and Forensic Medicine 1.1k
Countries citing papers authored by T. Meyer
This map shows the geographic impact of T. Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Meyer more than expected).
Fields of papers citing papers by T. Meyer
This network shows the impact of papers produced by T. Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Meyer. The network helps show where T. Meyer may publish in the future.
Co-authors
The 25 scholars most cited alongside T. Meyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 195 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hepatocellular carcinoma Hit paper breakdown → | 2022 | 1583 |
| 2 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 904 |
| 3 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 772 |
| 4 | Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma Hit paper breakdown → | 2021 | 726 |
| 5 | Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies Hit paper breakdown → | 2006 | 654 |
| 6 | A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability Hit paper breakdown → | 2012 | 533 |
| 7 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial Hit paper breakdown → | 2017 | 368 |
| 8 | Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial Hit paper breakdown → | 2019 | 333 |
| 9 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 331 |
| 10 | EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Hit paper breakdown → | 2024 | 302 |
| 11 | 2013 | 274 | |
| 12 | 2011 | 271 | |
| 13 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference Hit paper breakdown → | 2020 | 270 |
| 14 | 2016 | 253 | |
| 15 | PKC412--a protein kinase inhibitor with a broad therapeutic potential. | 2000 | 245 |
| 16 | 2010 | 226 | |
| 17 | 2000 | 221 | |
| 18 | 2009 | 216 | |
| 19 | 2020 | 206 | |
| 20 | 2001 | 171 |
About T. Meyer
T. Meyer is a scholar working on Hepatology, Oncology, Epidemiology, Neurology and Cancer Research, having authored 195 papers that have together received 14.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (74 papers), Neuroendocrine Tumor Research Advances (41 papers), Lung Cancer Research Studies (22 papers), Neuroblastoma Research and Treatments (19 papers), Liver Disease Diagnosis and Treatment (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer Mechanisms and Therapy (10 papers) and Pancreatic and Hepatic Oncology Research (9 papers). The work is most often cited by research in Hepatology (6.0k citations), Oncology (3.4k citations), Cancer Research (1.5k citations), Epidemiology (3.0k citations) and Pathology and Forensic Medicine (1.1k citations). T. Meyer has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include A. Vogel, Andrew Kenneth Burroughs, Anna Lena Saborowski, Gonzalo Sapisochín, Riad Salem, Josep Maria Llovet, Gordon J.S. Rustin, Martyn Evan Caplin, Bruno Sangro and Tu Vinh Luong. Their work appears in journals such as Annals of Oncology, Journal of Hepatology, British Journal of Cancer, European Journal of Cancer and Endocrine Related Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.